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Abstract
Gastric cancer induces systemic inflammatory reaction (SIR) manifesting with changes 
in counts of white blood cell fractions and concentrations of acute phase proteins, clot-
ting factors and albumins. Thus, protein-based scores or blood cell ratios (neutrophil 
to lymphocyte ratio (NLR); platelet to lymphocyte ratio (PLR)) are used to evaluate 
SIR. SIR tests are biologically justified by multiple clinically important and fascinating 
events including bone marrow activation, development of immune-suppressing imma-
ture myeloid cells, generation of pre-metastatic niches and neutrophil extracellular trap 
formation from externalised DNA network in bidirectional association with platelet 
activation. Despite biological complexity, clinical SIR assessment is widely available, 
patient-friendly and economically feasible. Here we present concise review on NLR, PLR, 
Glasgow prognostic score and fibrinogen – parameters that have prognostic role regard-
ing overall, cancer-free and cancer-specific survival in early and advanced cases. Tumour 
burden can be predicted helping in preoperative detection of serosal or lymph node 
involvement. Practical consequences abound, including selection of surgical approach in 
respect to tumour burden, adjustments in treatment intensity by prognosis or evaluation 
of chemotherapy response. The chapter also scrutinises main controversies including dif-
ferent cut-off levels. Future developments should include elaboration of complex scores 
as described here. SIR parameters should be wisely incorporated in patients’ treatment.
Keywords: gastric cancer, systemic inflammatory reaction, neutrophil to lymphocyte 
ratio, NLR, platelet to lymphocyte ratio, PLR, Glasgow prognostic score, fibrinogen
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1. Introduction
Gastric cancer remains an important issue in world oncology. In 2013, it ranked fifth by the 
global incidence and second by mortality [1]. Although the death rates have decreased sig-
nificantly in the USA and Europe over the previous 70 years, gastric cancer is characterised 
by poor prognosis and high mortality [2] except for early diagnosed cases. Thus, prognostic 
and predictive estimates are necessary to guide the intensity of treatment and to predict the 
efficacy of it. Different directions of prognostic evaluation have been studied, including clas-
sic means as tumour-node-metastasis (TNM) stage or patient’s Eastern Cooperative Oncology 
Group (ECOG) performance status [3], or novel approaches as the molecular tests [4].
Many tumours, including gastric cancer, evoke systemic inflammatory reaction (SIR). The 
systemic effects of cancer include alterations in bone marrow function, especially myelopoi-
esis. The production and release of leukocytes increases. In addition, immature myeloid cells, 
including the precursors of granulocytes and monocytes, are retained in early stages of differ-
entiation. Immature myeloid cells can act as immune suppressors and generate pre-metastatic 
niches, among other pathogenetic processes. Thus, it has even been stated that cancer is an 
inflammatory disease [5]. SIR shows complex associations with the local immune and inflam-
matory infiltrate in the tumour [6].
Cancer-related SIR involves cells of innate and adaptive immunity as well as soluble factors. 
Macrophages are recruited in tumour by hypoxia and tumour-released molecular agents 
including growth factors and cytokines [7]. Macrophage phenotype switch from tumour-
suppressing classical M1 to tumour-promoting M2 subtype promotes angiogenesis and 
immunosuppression. Platelets undergo activation that contributes to cancer progression and 
patient mortality [8]. Neutrophil activation can stimulate angiogenesis and metastatic spread. 
Neutrophil extracellular traps formed from externalised DNA network are bidirectionally 
associated with platelet activation and can contribute to cancer progression via several mecha-
nisms therefore neutrophil extracellular traps represent also an attractive treatment target [8]. 
Neutrophils are locally recruited in the cancer as well via chemokine signalling; they contrib-
ute to angiogenesis and increased blood vessel permeability. These molecular events highlight 
also the association between infection or surgery-induced inflammation [9, 10] and cancer 
relapse or metastatic spread. While innate immunity is generally thought to act as tumour 
enhancers, high numbers of infiltrating neutrophils [11] and macrophages [12] are shown to be 
protective in gastric cancer.
In contrast, lymphocytes representing the adaptive immunity are considered to have tumour 
suppressing effects [7] although contrary effects have been ascribed to certain subpopulations 
[13, 14].
There is increasing body of evidence that patients’ survival can vary despite equal TNM 
parameters. In turn, cancer can cause systemic inflammatory response that might be associ-
ated with prognosis and/or response to treatment. SIR can be evaluated by number or ratio 
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of serum neutrophils, lymphocytes, monocytes and platelets as well as by concentrations of 
acute phase proteins. These blood tests represent patient-friendly, widely available, globally 
standardised and cheap information that should be wisely incorporated in patients’ treatment 
[15]. Regarding the diagnostics of gastric cancer, several SIR parameters have been found to 
differ between gastric cancer patients and healthy controls. Such indicators include neutrophil 
to lymphocyte ratio [16–18], platelet to lymphocyte ratio, platelet count [18], mean platelet 
volume [18, 19] and red blood cell distribution width [18]. While these changes clearly indicate 
activation of systemic inflammatory reaction in gastric cancer, additional research is necessary 
to identify the diagnostic value of SIR parameters in the differential diagnosis between gas-
tric cancer and other gastric pathologies, including precancerous, inflammatory and ulcerative 
changes.
The correlation between neutrophil to lymphocyte ratio (NLR) and poor survival of gastric 
cancer patients is the best-known finding regarding SIR in gastric cancer [16, 17, 20]. High 
NLR is associated not only with shorter overall survival but also with worse progression-free 
survival [21]. In addition to the general association with survival, the prognostic value of 
NLR has been tested in specific clinical groups. Thus, NLR predicts post-operative survival 
of surgically treated patients with resectable cancer [22] and retains independent prognos-
tic role in elderly patients—an expanding group in Western population showing multiple 
ageing-related changes that could affect the immune and inflammatory processes [23]. For 
patients undergoing chemotherapy because of unresectable and recurrent advanced gastric 
cancer, NLR also shows independent prognostic significance [24]. NLR is an independent 
prognostic factor in metastatic gastric cancer [25] and in metastatic gastric cancer treated with 
chemotherapy [26]. The predictive value is limited in patients receiving palliative treatment 
for disseminated gastric cancer [21]. Some authors consider low NLR as an indicator for good 
prognosis and thus beneficial effect of surgical treatment in stage IV gastric cancer [27, 28].
Some research groups have found that complex assessment of SIR-related parameters has 
superior prognostic value. For instance, joint analysis of platelet count and NLR was found 
to predict post-operative survival more exactly [29]. Combined scoring of albumin and neu-
trophil to lymphocyte ratio was independently associated with overall survival and was 
especially accurate for patients with stage I–II gastric cancer [30]. Combined evaluation of 
pre-operative NLR and platelet to lymphocyte ratio (PLR) was independent predictor of sur-
vival after curative surgical resection of stage I–II gastric cancer [31].
SIR can highlight wider scope of clinical traits, including manifestations that are not directly 
related to surgery or oncologic treatment. For example, pre-operative anxiety and depression 
are significantly associated with NLR [32].
SIR assessment is more comprehensive than NLR analysis. Thus, pre-operative plasma fibrin-
ogen increases with gastric cancer stage and predicts worse recurrence-free and overall sur-
vival [33]. Similarly, levels of plasma albumin or the characteristics of platelets can provide 
significant data. Levels of C-reactive protein, original or modified Glasgow prognostic score 
can be used for analysis [3, 15].
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The systemic inflammatory reaction itself can be an adverse pathogenetic event, facilitating 
tumour angiogenesis or adhesion of circulating tumour cells to endothelium that would lead 
to the growth of metastasis. In addition, NLR correlates with other factors known to have 
adverse prognostic role. Among such parameters, presence of vascular and lymphatic inva-
sion as well as positive resection lines have been reported [22]. In several studies, NLR has 
been found to correlate with the stage of gastric cancer [16, 20–22]. NLR negatively correlates 
with mismatch repair protein deficiency [34]. NLR is associated with post-operative infec-
tious complications. Both factors show an independent significant association with poorer 
survival after gastrectomy [9].
The evaluation of SIR in gastric cancer patients is highly attractive. By increasing awareness 
of SIR parameters, simple and widely available blood tests can provide information that is 
helpful in shaping the care of gastric cancer patients from early stages to metastatic spread or 
locally advanced tumour.
However, unresolved issues remain. Except the prognostic value to NLR, many aspects 
as the correlation with tumour morphology, type by Lauren classification, invasive prop-
erties of cancer, grade, intensity of angiogenesis and microvascular density have been 
targeted by low number of studies. Only few meta-analyses have been conducted [21, 
35–37]. Few data are available on SIR parameters after treatment although it is known that 
post-chemotherapy NLR correlates with the response in patients with unresectable gastric 
cancer [38].
The practical unsolved questions include the comparison between NLR and other indicators 
of systemic inflammatory response, e.g., platelet to lymphocyte ratio [39], the significance of 
post-treatment NLR as well as cut-off values for practical use. The ultimate goal would be to 
create and validate an algorithm for fine-tuning of the treatment strategy in gastric cancer 
from early to advanced stages. Inflammatory markers other than NLR should be included; 
complex assessment hypothetically could be advised.
Thus, considering the high incidence and mortality of gastric cancer and the need for 
prognostic and predictive data, the present chapter will be devoted to the assessment of 
SIR in gastric cancer in order to develop practical recommendations how to adjust gastric 
cancer treatment by easily available and economically feasible simple blood tests for SIR 
parameters. Increased awareness of SIR characteristics is important to reach this aim.
2. Neutrophil to lymphocyte ratio in gastric cancer
Neutrophil to lymphocyte ratio is calculated as the ratio between the count of neutrophilic 
leukocytes and lymphocytes in peripheral blood. Thus, the parameter is easily available, 
especially in carefully examined cancer patients, and economically non-demanding. In fact, 
sufficient awareness and algorithm for interpretation are the only prerequisites to obtain an 
additional piece of information from routine blood tests.
Since the early reports [40, 41], NLR has been studied in relation to the prognosis of 
gastric cancer patients. Thus, Aliustaoglu et al. reported that high NLR was statistically 
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significantly associated with shorter median survival. In the same study, similar associa-
tion was found regarding high platelet to lymphocyte ratio and high absolute number of 
lymphocytes but no difference was found for neutrophil count, platelet count and mean 
platelet volume [41]. In another early study devoted to the prognostic significance of host- 
and tumour-related factors in patients with gastric cancer, white blood cell count, NLR, 
C-reactive protein (CRP) and albumin was found to have prognostic impact, along with 
age, haemoglobin level, tumour size as well as T and N characteristics. By multivariate 
analysis, NLR was an independent prognostic factor along with tumour size and T param-
eter [42].
At present, the association between NLR and different aspects of survival (overall, cancer-
specific, cancer-free or progression-free survival) remains one of the best substantiated aspects 
in the SIR research in gastric cancer.
2.1. NLR and survival: prognostic implications
The prognostic importance of NLR is shown over the whole course of gastric cancer, and is 
applicable to wide treatment spectrum—from surgically resectable cases, including early gas-
tric cancer, to advanced, recurrent or metastatic tumours subjected to non-surgical treatment. 
Most researchers have demonstrated that NLR is an independent prognostic factor, based on 
multivariate analysis [17]. However, in few studies, the association with survival is confirmed 
by univariate but not multivariate analysis [43–45]. Some of the reports are on better scores, 
e.g. Glasgow prognostic score had higher informativity in a large and homogeneous group of 
324 patients with stage III gastric cancer undergoing resection [43].
The prognostic value of NLR has been reported in different cancers, including lung, colorec-
tal and breast carcinoma, among others [46]. Gastric cancer also follows the same mecha-
nisms. In unselected cohort of patients diagnosed with gastric adenocarcinoma, high NLR 
(compared with the cut-off value 3) was a significant (p = 0.016), independent risk factor for 
poor survival [17].
Surgery is the mainstay of gastric cancer treatment, if the local and/or systemic tumour spread, 
or the general condition of the patient does not limit the possibilities of surgical intervention. 
In patients who have had curative surgery for gastric cancer, high NLR is significantly associ-
ated with poor prognosis [39], including overall survival [16, 47–49], cancer-specific survival 
[47], cancer-free survival [16, 47] and progression-free survival [25, 38, 50].
Thus, in a recent study of 162 patients with resectable gastric cancer, high pre-operative 
NLR (reaching or exceeding the median of 4.02) was associated with decreased overall 
and cancer-free survival, confirmed by Kaplan-Meier analysis [16]. In a significantly larger 
group of 1986 consecutive patients subjected to curative surgical treatment for gastric can-
cer, NLR was confirmed as an independent prognostic factor for overall survival, associated 
with hazard ratio of 1.4 [39]. Similarly, in 601 surgically treated gastric cancer patients, high 
NLR (reaching or exceeding 1.7) was a significant prognostic parameter for overall survival, 
confirmed as an independent factor by multivariate analysis. The hazard ratio was 2.12 [48]. 
Analogous observations were reported by Hsu et al. They assessed a large cohort of 1030 gas-
tric cancer patients subjected to complex treatment. In accordance with clinical indications, 
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subtotal or total gastrectomy along with spleen- and pancreas-sparing D2 lymphadenec-
tomy was performed, aiming to accomplish clear resection margins. Metastasectomy was 
considered depending on clinical symptoms and possibility of radical resections, and adju-
vant or palliative chemotherapy was offered for stage II–IV patients. In such a large group, 
showing the routine clinical diversity of gastric cancer presentation, high NLR (exceeding 
3.44) was an independent prognostic factor for overall survival, associated with hazard 
ratio of 1.57 [22].
In addition to significant statistical findings, the biological differences between groups also 
are remarkable. The 3- and 5-year survival rates in low versus (vs.) high NLR groups were 
71.0% vs. 55.1% and 64.1% vs. 47.2%, respectively [22]. Even more, the 5-year survival was 
29.9% in the high NLR group (reaching or exceeding 5.0) contrasting with statistically signifi-
cantly different value of 85.6% in patients who had low NLR [51].
The overall survival was 86.1 months in patients presenting with low NLR vs. 64.0 months 
in high NLR (reaching or exceeding 2.3) group [30]. Evaluating 156 surgically treated gastric 
cancer patients, the median survival in high vs. low NLR groups was 36 vs. 60 months while 
the five-year survival was 35% and 60%, and the median cancer-free survival was 12 and 
20 months, respectively. The survival differences retained significance in N0 patients: 5-year 
survival was 60% vs. 90%, p < 0.05. In this cohort, NLR was also recognised as an independent 
prognostic factor for overall survival [52].
In advanced gastric cancer (stage III–IV) patients subjected to gastrectomy with curative 
intent, high NLR was an independent predictor of overall survival at cut-off 2.0 correspond-
ing to median while cut-off value 3.0 (the 75th percentile) was an independent predictor of 
cancer-free survival. The median overall survival in high vs. low NLR was 21.4 and 45.3 
months while the progression-free survival in the redefined high and low NLR groups was 
12.8 vs. 27.9 months [53].
NLR retains prognostic significance for surgically treated gastric cancer patients in specific 
subgroups. For instance, in elderly gastric cancer patients (aged 75 years or older) treated 
by gastrectomy, high NLR (reaching or exceeding 1.83) was associated with worse survival. 
Again, NLR was confirmed as an independent risk factor by multivariate analysis. The bio-
logical differences were remarkable: the median survival associated with low vs. high NLR 
was 1209 vs. 587 days, respectively [16]. High NLR is associated with older age in some stud-
ies [9, 20, 44, 47, 54, 55] while others report no association [22, 38].
It is very important to identify high risk of cancer progression in early diagnosed cases. Some 
promising reports have been published. Combined score including NLR and albumin level 
was shown to have independent prognostic value exceeding the informativity of NLR as jus-
tified by higher area under curve (AUC). This score, further described in detail, retained the 
prognostic ability in stage I–II gastric cancer [30]. A complex score comprising NLR and PLR 
is another prognostic option, successfully tested in a stage I–II gastric cancer. NLR-PLR score 
showed a clear trend to improve the prognostic value of TNM staging [31].
Mohri et al. has reported very interesting findings regarding NLR in surgically treatable gas-
tric cancer cases. In 404 patients undergoing curative gastrectomy for gastric cancer, high NLR 
Gastric Cancer148
was an independent risk factor of post-operative infectious complications while it was not 
predictive of non-infectious complications. In turn, both high NLR and post-operative infec-
tious complications were independent risk factors of worse overall and cancer-specific sur-
vival [9]. The preceding NLR increase in patients later developing post-operative infectious 
complications but not in case of all complications was justified by Japanese scientists [10].
In contrast with the previously described findings, NLR was not informative regarding sur-
vival of gastric cancer patients having only local disease while it was significantly associated 
with survival in advanced cases [56]. Some negative findings, including the cited one, can be 
explained by small study group comprising only 53 patients with local disease and 50 with 
advanced cancer [56]. Evaluating Glasgow prognostic score, NLR and PLR in patients with 
resected stage III gastric adenocarcinoma, only Glasgow prognostic score along with TNM 
stage was independently associated with cancer-free and overall survival [43]. If the study 
design includes several SIR parameters, multivariate analysis could highlight only one of those.
Advanced or metastatic cancer represents a situation with continuously significant tumour 
burden, associated with ongoing inflammation, angiogenesis, antigenic stimulation and thus 
sustained SIR. The NLR has been evaluated in these situations as well. In 174 advanced gastric 
cancer patients treated with oxaliplatin/5-fluorouracil (FOLFOX), NLR was associated with 
overall survival but not with progression-free survival. NLR was also an independent predic-
tor of overall survival. Normalisation of NLR after one cycle of chemotherapy was significant 
and independent predictor of overall and progression-free survival [57]. Similar findings are 
reported by Jin et al. [58].
In unresectable and recurrent advanced gastric cancer patients treated by chemotherapy, high 
NLR (exceeding 4) was associated with significantly lower median survival [24]. Similarly, in 
another cohort comprising 143 cases of metastatic gastric cancer, high NLR was an independent 
prognostic factor. The overall and progression-free survival was 11.6 and 7.9 months in low 
NLR (less than 3.34) group contrasting with 8.3 and 6.2 months in patients having high NLR 
[25]. In 120 unresectable metastatic and advanced gastric cancer cases, treated by chemoradio-
therapy, baseline NLR predicted survival. The median overall and progression-free survival in 
high vs. low NLR group was 10 and 3 months vs. 18 and 6 months. Treatment-induced changes 
in NLR also predicted survival. Both baseline NLR and changes upon initiation of treatment 
predicted treatment outcomes [38]. This finding is in accordance with Cho et al., who also 
reported significantly higher chemotherapeutic disease control rate in metastatic advanced 
gastric cancer patients having low NLR, defined as less or equal to 3.0 [50]. Combined scores 
have been generated to evaluate the prognosis of metastatic gastric cancer as well [26].
Occasionally NLR shows association with survival by univariate but not multivariate analy-
sis. Thus, in a small group of 70 patients affected by locally advanced gastric cancer (stage 
III–IV) and treated by neoadjuvant chemotherapy, NLR was an independent predictor of 
overall survival. It was significantly associated with progression-free survival but was not an 
independent factor [59]. In a large group of 439 patients affected by metastatic or recurrent 
gastric cancer, NLR was significantly associated with overall survival in univariate but not 
multivariate analysis. Complex score was favoured by authors [60].
The prognostic findings regarding NLR in gastric cancer have been summarised in Table 1.
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Study group Survival References
Characteristics Size Overall Cancer-specific Cancer-free Progression-free
Unselected gastric 
adenocarcinoma
706 X
Multivariate
[17]
GC 245 X
Kaplan-Meier 
analysis of 
multicentre study 
data
[61]
Gastric adenocarcinoma 236 X
Multivariate
[62]
Surgically treated GC
Consecutive GC patients 
undergoing curative 
gastrectomy
404 X
Multivariate
X
Multivariate
[9]
Curative surgery for GC 288 X
Multivariate
[49]
Resectable GC 162 X
Kaplan-Meier 
analysis
X
Kaplan-Meier 
analysis
[16]
GC, subjected to curative 
surgery
1986 X
Multivariate
[39]
Surgically treated GC 
(R0)
601 X
Multivariate
[48]
GC patients undergoing 
gastrectomy
389 X
Multivariate
X
Multivariate
X
Multivariate
[47]
Surgically treated GC 
patients
207 X
Multivariate
X
Multivariate
[63]
GC subjected to radical 
surgery
291 X
Multivariate
[20]
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Study group Survival References
Characteristics Size Overall Cancer-specific Cancer-free Progression-free
GC subjected to 
gastrectomy
632 X
Univariate 
(significant)
Multivariate (NS)
[45]
GC subjected to 
potentially curative 
gastrectomy
156 X
Multivariate
[52]
Patients with resectable 
GC, including advanced 
cases
377 X
Multivariate
[64]
Surgically treated (total 
or subtotal gastrectomy) 
GC patients
220 X
Univariate 
(significant)
Multivariate (NS)
[44]
Gastrectomy with 
curative intent for stage 
III–IV GC
293 X
Multivariate
X
Multivariate
[53]
Curative gastrectomy 157 X
Multivariate
[65]
GC patients, undergoing 
gastrectomy
1028 X
Multivariate
[66]
Elderly patients (at least 
75 years old) undergoing 
gastrectomy
160 X
Multivariate
[23]
Curative resection, D2 
lymphadenectomy, 
adjuvant chemotherapy 
in stage II–III
873 X
Kaplan-Meier 
analysis
[30]
Resectable GC subjected 
to combined treatment
1030 X
Multivariate
[22]
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Study group Survival References
Characteristics Size Overall Cancer-specific Cancer-free Progression-free
Advanced, unresectable 
and/or metastatic GC
Unresectable and 
recurrent advanced GC, 
treated by chemotherapy
224 X
Multivariate
[24]
Metastatic GC treated by 
chemotherapy
256 X
Multivariate
[26]
Metastatic GC 143 X
Multivariate
X
Multivariate
[25]
Unresectable, advanced 
GC, treated by 
chemotherapy
120 X
Kaplan-Meier 
analysis
X
Kaplan-Meier 
analysis
[38]
Metastatic GC treated by 
chemotherapy
109 X
Kaplan-Meier 
analysis
X
Kaplan-Meier 
analysis
[67]
GC, stage IV with 
synchronous distant MTS
123 X
Multivariate
[27]
Metastatic advanced 
GC treated by palliative 
chemotherapy
268 X
Multivariate
X
Multivariate
[50]
Locally advanced GC 
treated by neoadjuvant 
chemotherapy
70 X
Multivariate
X
Univariate 
(significant)
Multivariate (NS)
[59]
Metastatic or recurrent 
GC
439 X
Univariate 
(significant)
Multivariate (NS)
[60]
Gastric Cancer
152
Study group Survival References
Characteristics Size Overall Cancer-specific Cancer-free Progression-free
Inoperable advanced or 
metastatic GC patients 
receiving chemotherapy
384 X
Univariate 
(significant)
Multivariate (NS)
[68]
Advanced GC patients 
treated by chemotherapy
174 X
Multivariate
X (dynamics, not 
baseline)
Multivariate
[57]
Advanced GC treated 
with neoadjuvant 
chemotherapy
46 X (baseline and 
dynamics)
X
Univariate 
(significant)
Multivariate (NS)
X (baseline and 
dynamics)
Multivariate
[58]
Metastatic unresectable 
advanced GC patients 
treated with palliative 
chemotherapy
104 X
Multivariate
[69]
Abbreviations: GC, gastric cancer; R0, resection line free of cancer; NS, not significant; MTS, metastasis.
Table 1. The prognostic value of NLR in gastric cancer patients.
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The cut-off levels vary widely among the studies. Most frequently, either the median value is 
selected as the cut-off [16, 70], or the relevant level is found by receiver operating characteris-
tic curve (ROC) analysis [30, 39]. Youden Index has been successfully employed to detect the 
optimal cut-off during ROC analysis [30]. This index is defined as the cut-off value showing the 
highest sum of specifity and sensitivity at the considered value; minus 1 [71]. Less frequently, 
the 75th percentile is used as the cut-off [44, 53]. Some research groups have applied more com-
plex approach, e.g. combining the patients groups with similar survival [17, 20]. The reported 
cut-off levels for NLR in gastric cancer patients are summarized in Table 2.
Interestingly, different cut-off values can reveal different information. Thus, Jung et al. has 
reported that cut-off 2.0 based on the median value was valuable in order to show that higher 
NLR is an independent risk factor for worse overall survival. However, when studying can-
cer-free survival, NLR was an independent risk factor by cut-off 3.0 corresponding to the 
75th percentile [53]. The necessity for different cut-offs in regard to the question of interest is 
indirectly demonstrated by mean NLR in different patient groups: 4.02 in T1–2; 6.54 in T3–4; 
4.81 in N0; 6.41 in N+; 5.00 in M0; 7.82 in M1; 4.74 in stage I–II cancers and 7.07 in stage III–IV 
cancers [47]. Jung et al. also observed statistically significant differences in median NLR by 
gastric cancer stage: 1.88 in stage III and 2.17 in stage IV [53].
2.2. Association with tumour features
2.2.1. Local tumour spread: T
Significant association between NLR and the invasion depth of gastric cancer is recognised 
since the early studies [65] and confirmed by more recent research [20]. The applied cut-off 
levels again vary widely. Thus, the association with increased depth of invasion has been 
demonstrated in patients whose high preoperative NLR level was defined as higher than or 
equal to 4.02 [16] or as exceeding the ROC-set cut-off value of 1.59 [55]. Significant difference 
in T1–2 vs. T3–4 distribution was reported by Deng et al. The mean NLR was 4.02 in T1–2 
cases and 6.54 in T3–4 cases [47].
Many studies have highlighted the association between NLR and serosal invasion that is classi-
fied as T4a. Such invasion represents a potential limit to surgical treatment if followed by exten-
sive peritoneal spread. NLR studies in regard to the tumour spread have led to the development 
of complex predictive scores to forecast serosal invasion. Hence, high NLR can be used as an 
independent predictive factor for T4 using cut-off 3.2 [73]. The high NLR (exceeding 3.44) group 
had significantly higher proportion of T4 when 1030 patients with resectable gastric cancer 
were assessed [22]. Serosal invasion was significantly more frequent in elderly patients having 
high NLR: 75.5% vs. 57.4% [23]. Finally, in a large prospective study enrolling 1131 surgically 
treated patients, high NLR (exceeding the median 3.5) was associated with deeper invasion: T3–
T4 tumours. The mean NLR was 2.51 in T3–T4 tumours vs. 2.19 in T1–T2 tumours. Within the 
frames of a complex score, NLR can be used to predict inappropriateness of gastrectomy [54].
The capacity of NLR to predict such tumour spread that would limit surgical treatment has been 
explored in combined model searching for either peritoneal or metastatic spread due to either 
gastric or oesophageal adenocarcinoma. Authors concluded that NLR reaching or exceeding 
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Study group Cut-off Study target Level of 
justification
Main conclusions References
Characteristics Size Value Approach
Unselected gastric 
adenocarcinoma
706 3 Complex OS Multivariate Higher NLR is 
associated with worse 
OS
[17]
GC 245 2.56 Ref. [40] OS Kaplan-Meier 
analysis
Multicentre 
study
High NLR is 
significantly associated 
with worse OS, 
presence of N+ and 
higher stage
[61]
Surgically treated GC
Operable GC 231 2.97 ROC analysis N Multivariate High NLR shows 
significant association 
with N+ in early 
GC but is not an 
independent factor
[72]
Stage I–II GC, subjected 
to radical (R0) 
surgery including D2 
lymphadenectomy
305 2.1 ROC analysis OS Multivariate Within the frames 
of complex NLR-
PLR score is an 
independent predictor 
of OS in stage I–II GC
[31]
Stage I–II GC, subjected 
to radical (R0) 
surgery including D2 
lymphadenectomy
305 3 Ref. [29] OS Multivariate Within the frames 
of complex score, 
including platelet 
count and NLR, is not 
the most informative 
predictor of OS by 
AUC assessment
[31]
Surgically treated T2 
GC
230 2.18 Median N Multivariate Higher NLR is 
associated with higher 
number of LN MTS 
and higher N
[70]
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Study group Cut-off Study target Level of 
justification
Main conclusions References
Characteristics Size Value Approach
Consecutive patients 
undergoing curative 
gastrectomy
404 3.0 ROC analysis OS
CSS
Post-operative 
complications
Multivariate Higher NLR is an 
independent risk 
factor for worse 
OS, CSS and post-
operative infectious 
complications
[9]
Curative surgery for 
gastric cancer
288 2.7 ROC analysis for 
survival
OS
Immune cell 
density within 
cancer
Multivariate Higher NLR is an 
independent risk 
factor for worse OS
Density of CD4 Ly 
is decreased in high 
NLR group while CD3 
and CD8 + Ly density 
shows no differences
[49]
Operable GC 492 1.59 ROC analysis N Multivariate High NLR is an 
independent factor, 
associated with N+
[55]
Curative resection, D2 
lymphadenectomy, 
adjuvant chemotherapy 
in high-risk stage II–III
873 2.3 ROC analysis OS Kaplan-Meier 
analysis
Multivariate
Although NLR is 
associated with OS, 
a complex score 
including NLR and 
albumin is more 
potent predictor of OS 
based on higher AUC 
in ROC analysis
[30]
Elderly patients 
(at least 75 years 
old) undergoing 
gastrectomy
160 1.83 ROC analysis OS Multivariate Higher NLR is an 
independent risk 
factor for worse OS
[23]
Surgically treated GC 601 1.7 ROC analysis OS Multivariate Higher NLR is an 
independent risk 
factor for worse OS
[48]
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Study group Cut-off Study target Level of 
justification
Main conclusions References
Characteristics Size Value Approach
Total or subtotal 
gastrectomy with 
lymphadenectomy
389 2.36 ROC analysis OS, CFS, CSS Multivariate Higher NLR is a 
significant risk factor 
for worse OS, CFS, 
CSS
[47]
Resectable GC 162 4.02 Median OS, CFS Kaplan-Meier 
analysis
Higher NLR is an 
associated with worse 
OS and CFS
[16]
Resectable gastric 
cancer subjected to 
combined treatment
1030 3.44 Survival tree 
assessment by R 
software
3 and 5-year OS 
rate
Multivariate Higher NLR is an 
independent risk 
factor for worse OS
[22]
Surgically treated GC 207 5/4 ROC analysis OS
CFS
Multivariate Higher NLR is an 
independent risk 
factor for worse OS. 
However, GPS has 
higher prognostic 
value
[63]
GC subjected to radical 
surgery
291 3.5 Complex 
assessment of 
survival by NLR 
intervals
OS
Tumour 
and patients 
characteristics
Multivariate High NLR is an 
independent 
prognostic factor for 
overall survival and is 
significantly associated 
with, age, tumour size, 
T and TNM stage
[20]
GC subjected to 
gastrectomy
632 1.83 ROC analysis OS Multivariate High NLR shows 
significant association 
with OS but is not 
an independent 
factor. Complex score 
preferred
[45]
GC subjected to 
potentially curative 
gastrectomy
156 2.34 Median OS Multivariate Higher NLR is an 
independent risk 
factor for worse OS
[52]
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Study group Cut-off Study target Level of 
justification
Main conclusions References
Characteristics Size Value Approach
Surgically treated GC, 
including non-radical 
cases
1131 3.5 Median Resection line 
status
Tumour 
characteristics
Mann Whitney 
test  
Fisher test
Univariate 
analysis
High NLR is 
associated with T3-4, 
G3-4, larger tumours, 
higher N and TNM 
stage
Within frames of 
complex score NLR 
can be used to predict 
inappropriateness of 
gastrectomy
[54]
Surgically treated GC 
patients
220 2.15 75th percentile OS Multivariate Higher NLR is a 
significant risk factor 
for OS by univariate 
but not multivariate 
analysis
[44]
Surgically treated GC, 
T2–4
262 3.2 ROC analysis T4 Multivariate High NLR is an 
independent factor, 
associated with T4
[73]
Gastrectomy with 
curative intent for stage 
III–IV GC
293 2.0 Median OS Multivariate Higher NLR is an 
independent risk 
factor for worse OS
[53]
Gastrectomy with 
curative intent for stage 
III–IV GC
293 3.0 75th percentile CFS Multivariate Higher NLR is an 
independent risk 
factor for worse CFS
[53]
Curative gastrectomy 157 5.0 Refs. [74, 75] CSS Multivariate Higher NLR is an 
independent risk 
factor for worse CSS
[65]
Advanced, unresectable and/or metastatic GC
Metastatic gastric 
adenocarcinoma treated 
by chemotherapy
256 3 Refs. [53, 66] OS Multivariate NLR is an independent 
risk factor
[26]
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Study group Cut-off Study target Level of 
justification
Main conclusions References
Characteristics Size Value Approach
Metastatic GC 143 3.34 Median OS Multivariate Higher NLR is an 
independent risk 
factor for worse OS
[25]
Metastatic GC treated 
by chemotherapy
109 2.5 Refs. [40, 58] OS
PFS
Kaplan-Meier 
analysis
High NLR is 
significantly associated 
with worse OS and 
PFS
[67]
Unresectable, advanced 
GC, treated by 
chemotherapy
120 4.62 Median OS
PFS
Kaplan-Meier 
analysis
Higher baseline 
NLR or increase of 
NLR after first-line 
chemotherapy is 
associated with worse 
OS and CFS
[38]
Unresectable, advanced 
GC, treated by 
chemotherapy
120 4.62 Median Response to 
chemotherapy
χ2 test Lower baseline NLR or 
lower NLR after first-
line chemotherapy 
was associated with 
improved response to 
chemotherapy
[38]
Advanced GC treated 
by chemotherapy//
Local GC treated by 
surgery and adjuvant 
chemoradiotherapy
50//53 2.75 Median OS Kaplan-Meier 
analysis
High NLR is 
significantly associated 
with worse OS in 
advanced but not 
local GC
[56]
GC (stage IV) with 
synchronous distant 
MTS
123 3.1 Median OS Multivariate Higher NLR is a 
significant risk factor 
for worse OS in the 
whole group and in 
surgically treated 
patients
[27]
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Study group Cut-off Study target Level of 
justification
Main conclusions References
Characteristics Size Value Approach
Metastatic advanced 
GC treated by palliative 
chemotherapy
268 3.0 Median OS, PFS
Response to 
chemotherapy
Multivariate Higher NLR is 
an independent 
risk factor for 
worse response to 
chemotherapy, OS 
and PFS
[50]
Inoperable advanced 
and metastatic GC 
patients receiving 
palliative chemotherapy
384 2.75 Median OS Multivariate High NLR shows 
significant association 
with OS but is not an 
independent factor
[68]
Advanced GC 
patients treated with 
chemotherapy
174 3 OS curve 
analysis
OS
PFS
Multivariate Low baseline NLR and 
normalisation of NLR 
were independent 
predictors of better OS. 
Normalisation of NLR 
was an independent 
predictor of better PFS.
[57]
Advanced GC treated 
by neoadjuvant 
chemotherapy
46 2.5 Ref. [40] OS
PFS
Multivariate [58]
Abbreviations: OS, overall survival; NLR, neutrophil to lymphocyte ratio; GC, gastric cancer; Ref., reference; N+, presence of metastases in regional lymph nodes; ROC, 
receiver operating characteristic curve; N, regional lymph node status in respect to metastases by tumour-nodes-metastasis (TNM) classification; R0, resection line free of 
tumour; PLR, platelet to lymphocyte ratio; AUC, area under the curve; T, local spread of primary gastric cancer by TNM classification; LN, lymph node; MTS, metastasis; 
CSS, cancer-specific survival; CD, cluster of differentiation; Ly, lymphocyte; CFS, cancer-free survival; GPS, Glasgow prognostic score; TNM, tumour-nodes-metastasis 
classification; G, grade; PFS, progression-free survival.
Table 2. Cut-offs of NLR in gastric cancer studies.
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the cut-off value of 3.28 is an independent predictor of undesirable tumour spread. The median 
NLR in operable patients vs. those having peritoneal or metastatic disease was 2.2 vs. 3.3 [76].
Negative findings have been published. Some of them could be easily explained by small 
group size, e.g. only 61 gastric cancer patients were enrolled in the study of Pietrzyk et al. [18]. 
However, no differences in T distribution by NLR were found by Kim et al. who analysed a 
large group of 601 patients [48]. No association between invasion depth and NLR was found 
in a multicentre study [61].
Large tumour size has shown association with high NLR [20, 22, 38, 53–55, 65, 77]. As T in 
gastric cancer is not defined by size, tumour size could become a confounding factor.
2.2.2. Metastases in regional lymph nodes: N
Metastatic involvement of regional lymph nodes is associated with worse prognosis, being 
especially important in the early stages of gastric cancer. Presence of lymph node metastases 
also limits and changes the treatment options as endoscopic resection is not feasible anymore 
but D2 lymphadenectomy becomes more appropriate than D1 lymphadenectomy. In addi-
tion, neoadjuvant treatment can be offered now to gastric cancer patients affected by lymph 
node metastases [55]. NLR can be used to predict lymph node metastasis. In a retrospec-
tive study of 230 surgically treated patients, affected by T2 gastric cancer, NLR exceeding 
the median value of 2.18 was associated with higher number of lymph node metastases and 
higher N characteristics. The findings were confirmed by multivariate analysis. The relative 
risk was as high as 4.15 and 7.09 in regard to high number of metastases and N stage, respec-
tively [70]. NLR at the cut-off level 1.59 (detected by ROC) was an independent factor associ-
ated with lymph node metastasis; however, higher informativity reflected by higher AUC 
was achieved by complex score (see further) including NLR, PLR and tumour-related factors 
[55]. The conclusions are justified by other researchers reporting correlation between NLR 
and N parameter since the early reports [65] until recent studies [77]. Thus, high NLR (exceed-
ing the ROC-set cut-off value of 1.59) was associated with high N [55] while low preoperative 
NLR level (less than 4.02) was associated with lower number of lymph node metastases [16]. 
The variability of applied cut-off values is evident.
Lymph node metastases were significantly more frequent in elderly patients having high NLR: 
83.0% vs. 55.6% [23]. In a large cohort of 1030 patients with resectable gastric cancer, high ratio 
of metastatic to examined lymph nodes defined as exceeding 0.18 was more frequent in those 
who had high NLR (greater than 3.44). Interestingly, in the same study N distribution showed 
only a trend to differences [22]. Significant difference in N0 vs. N+ distribution was reported 
by Deng et al. In addition, the mean NLR was 4.81 in N0 patients and 6.41 in N+ cases [47]. 
Statistically significant correlation between presence of lymph node metastasis, high NLR 
was confirmed in a multicentre study [61]. In a prospective study of 1131 surgically treated 
cases, high NLR (exceeding the median 3.5) was associated with higher N. The mean NLR 
was 2.31 in N0; 2.32 in N1; 2.43 in N2 and 2.75 in N3 cases [54].
Negative findings have been published as well. Some of them could be easily explained by 
small group size, e.g. only 61 gastric cancer patients were enrolled in the study of Pietrzyk 
Systemic Inflammatory Reaction in Gastric Cancer: Biology and Practical Implications...
http://dx.doi.org/10.5772/intechopen.69723
161
et al. [18]. No differences in N distribution by NLR were found by Kim et al. who analysed a 
large group of 601 patients [48] and Yu et al. who assessed another significant cohort of 291 
patients. In the same study, association with T and TNM stage was significant [20]. There was 
no correlation between NLR and N in a reasonable group of 262 surgically treated patients 
affected by T2–T4 gastric cancer while correlation with T in the same study was meaningful. 
The cut-off in this study was detected by ROC and was 3.2 [73].
Some reports have re-evaluated the meaning of NLR in predicting N status, arriving to less 
positive conclusions. In early gastric cancer (T1a–T1b), NLR was significantly associated with 
presence of lymph node metastases. The mean NLR was 2.07 in N0 group while it increased to 
2.60 in N+ group. However, by multivariate analysis NLR was not an independent prognostic 
factor. Complex score not including NLR was more informative for preoperative estimation 
of lymph node metastases [72].
2.2.3. Presence of distant metastases: M
Presence of distant metastasis has also been associated with higher NLR [38, 77]. Metastatic 
tumours were significantly more frequent in patients who had high NLR (exceeding 3.44) 
assessing 1030 patients with resectable gastric cancer [22]. Significant difference in M0 vs. M1 
frequencies by NLR groups was reported by Deng et al. In addition, the mean NLR was 5.00 
in M0 cases and 7.82 in M1 cases [47].
In a large study of 491 gastric cancer patients, NLR was significantly associated with perito-
neal metastasis. However, it was not an independent predictive factor for peritoneal spread, 
while tumour morphology, serum level of carbohydrate antigen CA19-9 and lymphocyte 
count retained independent predictive value [78]. In contrast, evaluating CRP, activated par-
tial thromboplastin time, NLR and hypoalbuminemia, NLR was identified as an independent 
risk factor of the presence of peritoneal metastasis. The cut-off level was set at 2.37 [79].
2.2.4. TNM stage
Considering the previously discussed links between NLR and TNM parameters, correlation 
with TNM stage could be expected as well. Indeed, advanced TNM stage was significantly 
associated with high NLR [9, 20, 44, 47, 65, 77]. High NLR (exceeding the ROC-set cut-off 
value of 1.59) was associated with high TNM stage [55]. The mean NLR was 4.73 in stage I–II 
and 7.07 in stage III–IV [47]. In advanced gastric cancer (stage III–IV) patients, there still was 
difference between stage III and IV [53].
Statistically significant correlation between cancer stage and high NLR was confirmed also by 
multicentre [61] and prospective study design [54]. In a prospective study of 1131 surgically 
treated patients, high NLR (exceeding the median 3.5) was associated with higher TNM stage. 
The mean NLR was 2.13 in stage I, 2.40 in stage II, 2.53 in stage III and 2.60 in stage IV [54].
Regarding negative reports, no NLR differences by TNM stage were found by Kim et al. who 
analysed a large group of 601 patients [48].
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2.2.5. Histological type and grade (G)
The association between NLR and cancer grade is more controversial. The cancer grade was 
not different between high and low NLR groups in a cohort of 143 metastatic gastric cancer 
cases as well as in 389 patients who underwent gastrectomy or in 293 gastric cancer patients 
diagnosed in stage III–IV [22, 25, 47, 53]. No difference by differentiation degree (G1–2 vs. G3) 
was found by Yu et al. [20].
In contrast, high NLR was associated with differentiated (vs. undifferentiated) gastric cancer 
[9]. High differentiation degree (vs. moderate and poorly differentiated cases) was associ-
ated with low NLR. In the same study, no differences were observed regarding proliferation 
fraction by Ki-67 [38]. High NLR (exceeding the ROC-set cut-off value of 1.59) was associ-
ated with high grade [55]. In a prospective study of 1131 surgically treated patients, high 
NLR (exceeding the median 3.5) was associated with poor differentiation or undifferentiated 
tumours while low NLR—with high and moderate differentiation. The relevant mean NLR 
values were 2.46 in G3–G4 vs. 2.31 in G1–G2 cancers [54].
There was no correlation between NLR and histological differentiation in a large group of 
262 surgically treated patients affected by T2–T4 gastric cancer while correlation with T in the 
same study was meaningful. The cut-off in this study was detected by ROC and was 3.2 [73]. 
No correlation between histological type of cancer and NLR was observed in a prospective 
study of 1131 surgically treated patients [54]. No differences in histology distribution by NLR 
were found by Kim et al. who analysed a large group of 601 patients [48]. Histological types 
(papillary, tubular, poorly differentiated, mucinous, signet ring cell carcinoma) were scruti-
nized by Deng et al., also finding no association with NLR level [47].
No NLR differences were observed between Lauren types: intestinal vs. diffuse [38, 53, 65] 
that might explain the lack of association with HER-2 protein expression [38].
Low NLR shows significant correlations with mismatch repair deficiency [34]. In can-
cer tissues, the density of CD4-positive lymphocytes was significantly decreased in high 
NLR group while the density of CD3 and CD8-positive lymphocytes was not associated 
with NLR [49]. Although NLR correlated with survival, it did not correlate with tumour-
infiltrating lymphocytes [62]. Regarding cytokines and angiogenic factors, serum levels 
of osteopontin and interleukin 6 were significantly associated with NLR in gastric cancer 
patients [80]. NLR is significantly associated with helper T lymphocyte Th1/Th2 ratio in 
blood [65].
2.2.6. Manifestations of invasive growth
Only few scientists have assessed the relations between NLR and such manifestations of inva-
sive growth as perineural, lymphatic and vascular invasion. Theoretically, such association 
could be hypothesised on the basis of prognostic value of NLR and the correlations between 
NLR and metastatic cancer spread. However, at present, negative reports predominate 
although are not unequivocal.
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The frequency of perineural growth was not different between high and low NLR groups 
[22]. The frequency of lymphovascular invasion also was not different between high and low 
NLR groups in a cohort of 143 metastatic gastric cancer cases [25]. In contrast, vascular or 
lymphatic invasion was significantly more frequent in patients who had high NLR (exceeding 
3.44) assessing 1030 cases of resectable gastric cancer. Hypothetically, the higher capacity for 
invasive growth could be the reason of more frequent occurrence of R1 in patients present-
ing with high NLR. However, association between NLR and resection line status (R0 vs. R1 
vs. R2) was found by Jung et al., who observed no differences in the frequency of lymphatic, 
vascular and perineural growth regarding NLR level [53].
2.3. The diagnostic role of NLR and confounding factors
Several haematological parameters, including NLR, are significantly higher in gastric cancer 
patients than in healthy individuals [18]. A number of studies have confirmed that patients 
affected by gastric carcinoma have significantly higher NLR than healthy controls [16, 17]. 
NLR was also higher in gastric cancer patients if compared with persons having adenoma 
or benign gastrointestinal stromal tumour: 2.17 vs. 1.62. Excluding the confounding factors, 
NLR was an independent predictor of gastric cancer, associated with the odds ratio of 1.446, 
p = 0.005 [77].
NLR is influenced by smoking [81]. Such differences are reported in gastric cancer patients 
as well [25] while other researchers have found no difference [47]. Non-oncological diseases, 
including both inflammations and such frequent non-inflammatory pathologies as diabetes 
mellitus and atrial fibrillation, among others, can also influence NLR [82]. Thus, SIR should 
be assessed within the frames of complex patient evaluation.
2.4. Meta-analyses of NLR in gastric cancer
Several meta-analyses of NLR in gastric cancer have been carried out. Sun et al. have assessed 
19 studies of NLR in gastric cancer. They confirmed the association between high NLR and 
worse overall, progression- or cancer-free survival, and higher stage. The predictive role was 
lost for stage IV patients who received palliative surgery only [21]. Nineteen studies were 
subjected to meta-analysis by Xin-Ji et al. [37]. Elevated NLR was associated with shorter 
overall (odds ratio (OR) 1.65; 95% CI = 1.47–1.83) and shorter cancer-free survival (OR 1.61; 
95% CI = 1.28–1.94). Regarding the tumour characteristics, NLR was associated with pres-
ence of lymph node metastasis, and high T (T3 + T4) and high stage (III–IV). The odds 
ratio for lymph node metastasis, 1.70 (95% CI = 1.05–2.75), for T3 or T4 cancer 2.93 (95% 
CI = 2.27–3.78) and for stage III–IV: 1.87 (95% CI = 1.48–2.35) as reported by Xin-Ji et al. [37]. By 
meta-analysis performed by Chen et al. [36], high NLR was associated with poor overall sur-
vival (hazard ratio (HR) 2.16; 95% CI = 1.86–2.51) and progression-free survival (HR 2.78; 95% 
CI = 1.95–3.96). In a meta-analysis of 10 studies, higher NLR was associated with worse over-
all (HR 1.83; 95% CI = 1.62–2.07), progression-free (HR 1.54; 95% CI = 1.22–1.95) and cancer-
free (HR 1.58; 95% CI = 1.12–2.21) survival [35].
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3. Platelet to lymphocyte ratio in gastric cancer
3.1. PLR and survival: prognostic implications
Similarly to NLR, platelet to lymphocyte ratio (PLR) has been evaluated as a prognostic and 
diagnostic marker of gastric cancer. Although the prognostic role has been shown both in 
surgically treatable and advanced gastric cancer cases, the data are controversial.
Some research groups have demonstrated that PLR could help to predict overall and cancer-
free survival of surgically treated gastric cancer patients. Thus, in 377 patients who under-
went curative resection for gastric cancer, high PLR was an independent predictive factor for 
worse overall survival [64]. In 162 patients diagnosed with resectable gastric cancer, high PLR 
correlated with decreased both overall and cancer-free survival [16].
Later, evaluating several blood test parameters (PLR, NLR, absolute count and relative propor-
tion of neutrophils and lymphocytes, counts of platelets, white and red blood cells as well as 
mean platelet volume) in 451 surgically treated gastric cancer patients, high PLR was the only 
independent prognostic marker for poor overall survival, associated with hazard ratio of 1.4 
(95% CI = 1.0–1.9). Hence, in this study preoperative PLR was more informative than NLR [83].
PLR has been successfully implemented in complex prognostic score (along with NLR, see 
also the further description) in order to assess the prognosis in stage I–II gastric cancer. The 
created score was an independent predictor of overall survival and retained prognostic sig-
nificance both in stage I and stage II [31].
In contrast, several studies either preferred the NLR as more informative SIR marker, or 
failed to identify the independent prognostic role of PLR although significant association 
with survival parameters was found by univariate analysis. In 389 gastric cancer patients 
who have undergone gastrectomy, elevated PLR was significantly associated with worse 
overall, cancer-specific and cancer-free survival. The cut-off was estimated by ROC analysis 
and was 132. However, as a prognostic factor for overall survival, cancer-specific survival 
and cancer-free survival, PLR was not superior to NLR [47]. PLR was not an independent 
prognostic factor for overall survival in large Chinese cohort of 591 gastric cancer patients 
although it was significantly associated with survival by univariate analysis. In the same 
study, NLR along with age and TNM stage was shown to be an independent prognostic 
factor [84]. Assessing 207 gastric cancer patients treated by resection, univariate analysis dis-
closed significant association of PLR (along with serum CRP, albumin, Glasgow prognostic 
score (GPS), NLR, cancer grade and TNM stage) with overall survival and cancer-specific 
survival. However, by multivariate analysis, PLR was not an independent predictor of sur-
vival, contrasting with NLR, GPS, TNM stage and cancer grade. Glasgow prognostic score 
and TNM stage were the most robust of the assessed prognostic parameters [63]. Evaluating 
different SIR markers, namely, GPS, NLR and PLR, as prognostic variables in 324 patients 
with resected stage III gastric adenocarcinoma, only Glasgow prognostic score along with 
TNM stage was independently associated with cancer-free and overall survival while PLR 
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was associated with GPS [43]. By univariate analysis, both NLR and PLR were associated 
with overall survival of gastric cancer patients after gastrectomy. However, none of these 
parameters was identified as an independent factor by multivariate analysis in this study 
[45]. A study of 1986 consecutive gastric cancer patients was directly targeting the issue if 
PLR of NLR is better as a prognostic factor of gastric cancer. Although high PLR was signifi-
cantly associated with poor prognosis it was not an independent risk factor for decreased 
overall survival in contrast to NLR. Thus, NLR was preferred [39].
Finally, negative results are reported. In a multicentre study of 245 gastric cancer patients, 
PLR was not associated with survival [61].
In advanced gastric cancer, many studies have revealed significant and independent associa-
tion between PLR and survival. However, controversial findings still are reported.
High PLR (exceeding 160) along with high NLR (reaching or exceeding 2.57) and high abso-
lute number of lymphocytes (reaching or exceeding 1500/mm3) were significantly associated 
with shorter median overall survival of 168 locally advanced gastric cancer patients. The 
median survival in high vs. low PLR groups was 27 vs. 45 months [41].
In advanced unresectable gastric cancer, low PLR (less than 235) correlated with less metas-
tasis and improved response to chemotherapy, longer overall survival and progression-free 
survival. Changes in PLR after first-line chemotherapy also were indicative of prognosis: sur-
vival and response to treatment was better in cases that retained low PLR or switched to low 
PLR group during treatment [38].
In a cohort of 109 metastatic gastric cancer patients treated by chemotherapy, high PLR 
(exceeding the cut-off 160) was associated with significantly shorter progression-free and 
overall survival [67].
In 174 advanced gastric cancer cases treated by chemotherapy, low PLR and normalisation of 
PLR after one cycle of chemotherapy were independent prognostic markers for better overall 
survival. Normalisation of PLR was also associated with longer progression-free survival: 5.6 
months vs. 3.4 months [57].
In a relatively small study group, PLR lacked prognostic role in 53 patients affected by local 
gastric cancer and treated with surgery and adjuvant chemotherapy while it had significant 
prognostic meaning in 50 advanced cases treated by chemotherapy. Interestingly, high plate-
let count was associated with better overall survival in patients having local disease [56].
Again, many studies have identified significant but not independent association between PLR 
and survival. In 439 patients affected by metastatic or recurrent gastric cancer, PLR (along 
with NLR, modified Glasgow prognostic score, previous histology with neural and vascu-
lar invasion, albumin, CRP and haemoglobin level) was significantly associated with over-
all survival, but it was not an independent prognostic factor. In this study design, modified 
Glasgow prognostic score was the only inflammation-related parameter that was indepen-
dently associated with survival by multivariate analysis [60]. In 384 patients affected by inop-
erable advanced or metastatic gastric cancer and treated by palliative chemotherapy, PLR (as 
well as NLR, leucocytosis, elevated number of neutrophils or platelets, decreased lymphocyte 
count, hypoalbuminemia, high CRP and Glasgow prognostic score) showed association with 
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overall survival by univariate analysis. By multivariate assessment, PLR had no independent 
meaning. Only elevated count of neutrophils and Glasgow prognostic score were indepen-
dent survival predictors by multivariate analysis [68].
As the prognostic role of PLR in gastric cancer is controversial, meta-analyses also have brought 
contrary opinions. Thus, in a meta-analysis of 8 studies comprising 4513 patients with gastric 
cancer, there was no association between elevated PLR and overall survival: the hazard ratio 
was 0.99 (95% CI = 0.9–1.1) as described by Xu et al. [85]. In another meta-analysis comprising 14 
cohorts and 6280 cases, PLR was associated with poor overall survival (HR 1.3; 95% CI 1.1–1.5) 
but not with worse cancer-free survival (HR 1.6; 95% = CI 0.9–2.9). High PLR predicted poor 
survival in Caucasians, patients receiving chemotherapy and patients at advanced stage [86].
In parallel with NLR research, diversity of cut-off levels have been applied in PLR studies 
(Table 3).
In 377 patients who underwent curative resection for gastric cancer, PLR was independently 
associated with the development of post-operative complications [64].
3.2. Association with tumour features
3.2.1. Local tumour spread: T
PLR has been evaluated for the association with tumour features, mainly—TNM parameters, 
representing the oncological mainstay. The association between high PLR and deeper inva-
sion has been confirmed in 162 patients diagnosed with resectable gastric cancer [16], in a 
larger cohort of 451 surgically treated gastric cancer patients [83] and in a multicentre study 
of 245 gastric cancer patients [61]. In a meta-analysis of 8 studies comprising 4513 patients 
with gastric cancer, elevated PLR also showed association with deeper invasion (T3–T4). The 
relevant odds ratios was 2.01 (95% CI 1.49–2.73) as reported by Xu et al. [85]. In addition, in 
a large cohort of 451 surgically treated gastric cancer patients, high PLR was associated with 
larger tumour size [83].
3.2.2. Metastases in regional lymph nodes: N
In patients diagnosed with resectable gastric cancer, high PLR correlated with higher num-
ber of lymph node metastases [16]. The association between high PLR and presence of 
lymph node metastasis was re-confirmed by a meta-analysis of 8 studies comprising 4513 
patients with gastric cancer. Elevated PLR showed association with lymph node metastasis 
with the relevant odds ratio of 1.50 (OR 1.24–1.82) as reported by Xu et al. [85]. In another 
meta-analysis comprising 14 cohorts and 6280 cases, elevated PLR also was significantly 
associated with lymph node metastases [86]. However, in a multicentre study of 245 gastric 
cancer patients, PLR was not associated with N [61].
PLR has been investigated as predictive factor for lymph node metastases in a cohort of surgi-
cally treatable gastric cancer comprising 492 patients. PLR was identified as an independent 
predictive factor for lymph node metastasis and along with other independent prognostic 
factors that can be determined preoperatively was included in scoring system. This complex 
Systemic Inflammatory Reaction in Gastric Cancer: Biology and Practical Implications...
http://dx.doi.org/10.5772/intechopen.69723
167
Study group Cut-off Study target Level of 
justification
Main conclusions References
Characteristics Size Value Approach
Patients with confirmed 
GC diagnosis
103 170 Median OS Kaplan-Meier 
analysis
PLR is associated 
with worse OS in 
advanced but not 
local GC
[56]
Patients with confirmed 
GC diagnosis
245 160 Ref. [87] OS Kaplan-Meier 
analysis
Multicentre study
PLR correlated 
with T and stage 
but not survival
[61]
Surgically treated GC
GC patients subjected 
to curative resection
873 117 ROC analysis OS Kaplan-Meier 
analysis
Higher PLR is 
associated with 
worse OS
[30]
Operable GC patients 492 155.67 ROC analysis N Multivariate PLR was an 
independent factor 
predicting N+ and 
was incorporated 
in complex score
[55]
Operable patients with 
early GC
312 106 ROC analysis N Multivariate PLR was an 
independent factor 
predicting N+ and 
was incorporated 
in complex score
[72]
Surgically treated GC 207 3-tiered complex 
scoring
ND OS
CFS
Multivariate PLR was associated 
with OS and CFS 
by univariate but 
not multivariate 
analysis
[63]
GC patients undergoing 
gastrectomy
632 140 ROC analysis OS Multivariate PLR was associated 
with OS by 
univariate but 
not multivariate 
analysis
[45]
Gastric Cancer
168
Study group Cut-off Study target Level of 
justification
Main conclusions References
Characteristics Size Value Approach
Resectable GC 162 208 Median OS, CFS Kaplan-Meier 
analysis
Higher PLR is 
associated with 
worse OS and CFS
[16]
GC treated by total or 
subtotal gastrectomy 
with lymphadenectomy
389 132 ROC analysis OS, CFS, CSS Multivariate Higher PLR is 
significantly 
associated with 
worse OS, CFS, CSS
[47]
Advanced, unresectable and/or metastatic GC
Unresectable, advanced 
GC, treated by 
chemotherapy
120 235 Median OS
PFS
Kaplan-Meier 
analysis
Multivariate
Higher baseline 
PLR or increase of 
PLR after first-line 
chemotherapy is 
associated with 
worse OS and CFS
[38]
Unresectable, advanced 
GC, treated by 
chemotherapy
120 235 Median Response to 
chemotherapy
χ2 test Lower baseline 
PLR or lower PLR 
after first-line 
chemotherapy was 
associated with 
improved response 
to chemotherapy
[38]
Metastatic GC treated 
by chemotherapy
109 160 Refs. [40, 58] OS
PFS
Kaplan-Meier 
analysis
High PLR is 
significantly 
associated with 
worse OS and PFS
[67]
Abbreviations: GC, gastric cancer; OS, overall survival; PLR, platelet to lymphocyte ratio; Ref, reference; T, local spread of primary gastric cancer by tumour-nodes-
metastasis (TNM) classification; ROC, receiver operating characteristic curve; N, regional lymph node status in respect to metastases by (TNM) classification; N+, presence 
of metastases in regional lymph nodes; ND, no data available; CFS, cancer-free survival; CSS, cancer-specific survival.
Table 3. Cut-offs of PLR in gastric cancer studies.
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score consisted of NLR (cut-off 1.59), PLR (cut-off 155.67), T/depth of invasion, macroscopic 
type according to Bormann and tumour size [55].
As previously outlined, lymph node status is crucial to select the most appropriate treatment 
in early gastric cancer. PLR has been analysed in this context. In a retrospective assessment 
of 312 early gastric cancer cases subjected to surgical treatment, high PLR along with high 
NLR was significantly associated with lymph node metastases. Although both PLR and NLR 
showed this association by univariate analysis, only PLR was identified as an independent 
risk factor by multivariate analysis. Thus PLR, but not NLR was included in a complex score. 
The scoring system was based on the identified independent risk factors: PLR (cut-off 106, 
based on ROC analysis), age, tumour size, grade and depth of invasion and successfully vali-
dated in a prospective training set [72].
3.2.3. TNM stage
In patients diagnosed with resectable gastric cancer, high PLR correlated with higher stage 
[16]. The association between high PLR and higher stage was confirmed in a multicentre 
study of 245 gastric cancer patients [61]. When a meta-analysis of 8 studies was performed 
comprising data on 4513 patients with gastric cancer, elevated PLR showed association 
with advanced cancer stage (III–IV). The relevant odds ratios was 1.99 (95% CI 1.60–2.46) as 
reported by Xu et al. [85].
Generally, PLR can accurately reflect tumour burden. In the study carried out by Cetinkunar et 
al., the 228 cases were classified as early vs. advanced and non-metastatic vs. metastatic ones. 
PLR could discriminate the groups in both models. The mean PLR values were 160.3 in early 
and 231.6 in advanced gastric cancer; 192.7 in non-metastatic and 251.0 in metastatic cases [88].
3.3. The diagnostic role of PLR
The diagnostic role of PLR has been explored as well. Thus, the mean values of PLR were 
significantly higher in gastric cancer patients than in healthy controls [16, 18]. The parameter 
might seem promising as it is not affected by smoking in contrast to NLR [81].
3.4. Meta-analyses of PLR in gastric cancer
Several meta-analyses of PLR have been devoted to PLR in gastric cancer, yielding partially 
conflicting results. In a meta-analysis of 8 studies comprising 4513 cases of gastric carci-
noma, elevated PLR correlated with lymph node metastasis, deeper invasion (T3–T4) and 
advanced cancer stage (III–IV) but it was not predictor of overall survival. The relevant odds 
ratios were 1.50 (95% CI = 1.24–1.82) for N+, 2.01 (95% CI = 1.49–2.73) for T3–T4 and 1.99 
(95% CI = 1.60–2.46) for stage III–IV [85].
Fourteen cohorts and 6280 cases were re-evaluated within the frames of another meta-anal-
ysis. Authors found out that PLR was associated with poor overall survival but not with 
cancer-free survival. High PLR predicted poor survival in Caucasians, patients receiving 
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chemotherapy and patients at advanced stage. Despite the controversies regarding sur-
vival, the association with lymph node metastases was reconfirmed [86].
Zhou et al. carried out a general meta-analysis devoted to the prognostic value of PLR in dif-
ferent cancers [89]. There was significant association between elevated PLR and worse overall 
survival (hazard ratio 1.60; 95% CI = 1.35–1.90). In the subgroup of gastric cancer, the HR was 
1.35 (95% CI 0.80–2.25).
4. Peripheral blood monocytes in gastric cancer assessment
Although macrophages are a significant component of tumour microenvironment, quite few 
studies have been devoted to the prognostic role of monocytes in relation with other cells in 
peripheral blood of gastric cancer patients.
However, in a recent large study enrolling 3243 gastric cancer patients, high monocyte to white 
cell ratio (MWR) was identified as an independent prognostic factor of poor survival. In the 
same study, high NLR, high PLR, high monocyte to lymphocyte ratio, high neutrophil to white 
cell ratio, low lymphocyte to white cell ratio (LWR) were associated with survival in univari-
ate analysis, but only low LWR and high MWR were independent prognostic factors for poor 
survival [90].
In gastric cancer patients who have undergone gastrectomy, decreased lymphocyte to mono-
cyte ratio (LMR) was significantly associated with worse overall survival, cancer-specific 
survival and cancer-free survival. The cut-off was estimated by ROC analysis and was 4.95. 
However, as a prognostic factor for overall survival, cancer-specific survival and cancer-free 
survival, LMR was not superior to NLR [47].
5. Glasgow prognostic score in gastric cancer
Glasgow prognostic score is considered the prognostic milestone of SIR assessment in malig-
nant tumours [91]. It is detected on the basis of the prototypic acute phase protein, C-reactive 
protein and albumin levels in blood serum. CRP is a non-specific, but sensitive marker of sys-
temic inflammatory response, produced as a response to pro-inflammatory cytokines includ-
ing interleukins IL-1 and IL-6 as well as tumour necrosis factor TNF. Hypoalbuminemia can 
be caused by malnutrition and cancer cachexia or by systemic inflammation [68]. GPS includes 
both estimates of elevated acute phase response and malnutrition, resulting in considerable 
sensitivity [68]. Later, two alterations of Glasgow prognostic score have been developed—the 
modified GPS and high-sensitivity GPS. In the modified GPS, albumin level influences the 
score only if CRP is increased [31]. However, the definitions also show variability between 
authors [92]. High-sensitivity GPS differs from the original GPS by lower cut-off level for CRP 
[93]. The definitions of GPS and its modifications are summarised in Table 4.
Systemic Inflammatory Reaction in Gastric Cancer: Biology and Practical Implications...
http://dx.doi.org/10.5772/intechopen.69723
171
5.1. Glasgow prognostic score and survival
Glasgow prognostic score has high informativity both in surgically treatable and advanced, 
unresectable and/or metastatic gastric cancer. Thus, evaluating Glasgow prognostic score, 
NLR and PLR in 324 patients with resected stage III gastric adenocarcinoma, only Glasgow 
prognostic score along with TNM stage was independently associated with overall and cancer-
free survival [43]. In 207 gastric cancer patients who underwent surgery, GPS along with NLR, 
PLR, CRP, albumin and TNM stage were significantly associated with overall and cancer-free 
Score Definition References
Glasgow prognostic score [68]
0 CRP < 10 mg/L AND albumin ≥ 35 
g/L
1 One high-risk finding: CRP ≥ 10 mg/L 
OR albumin < 35 g/L
2 Both high-risk findings: CRP ≥ 10 
mg/L AND albumin < 35 g/L
Modified Glasgow prognostic score [31]
[94]0 CRP ≤ 10 mg/L irrespective of 
albumin level
1 Increased CRP on the background of 
normal albumin level: CRP > 10 mg/L 
AND albumin ≥ 35 g/L
2 Increased CRP and 
hypoalbuminemia: CRP > 10 mg/L 
AND albumin < 35 g/L
Modified Glasgow prognostic score by Hirashima et al. [92]
0 CRP ≤ 5 mg/L AND albumin ≥ 38 g/L
1 One high-risk finding: CRP > 5 mg/L 
OR albumin < 38 g/L
2 Both high-risk findings: CRP > 5 
mg/L AND albumin < 38 g/L
High-sensitivity Glasgow prognostic score [93]
0 CRP ≤ 3 mg/L AND albumin ≥ 35 g/L
1 One high-risk finding: CRP > 3 mg/L 
OR albumin < 35 g/L
2 Both high-risk findings: CRP > 3 
mg/L AND albumin < 35 g/L
Abbreviations: CRP, C-reactive protein.
Table 4. Glasgow prognostic score and its modifications.
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survival. However, only GPS and TNM were independent prognostic factors; therefore in this 
study, GPS was favoured as the most informative SIR parameter [63]. By multivariate analy-
sis, GPS was independent predictor of overall survival in 425 surgically treated gastric cancer 
patients who had normal serum levels of carcinoembryonic antigen [91]. In a large cohort of 
1017 patients subjected to curative resection of gastric cancer, GPS was an independent prog-
nostic factor for overall survival [95].
In a homogeneous group of 88 gastric cancer patients undergoing only surgical treatment, 
increasing GPS was an independent predictor of worse overall survival and perioperative 
mortality. The median survival by GPS 0 vs. 1 vs. 2 was 25.2 vs. 15.3 vs. 5.8 months. The peri-
operative mortality in the same subgroups was 0.0% vs. 20.0% vs. 80.0% [96]. However, the 
GPS capacity to predict complications is not straightforward. In contrast with the previous 
report, assessing 1017 patients subjected to curative resection of gastric cancer, GPS was not 
associated with the incidence of complications [95].
Variations of GPS have been successfully tested. In a large group of 236 gastric cancer patients 
who underwent gastrectomy, high-sensitivity GPS after surgery was a significant prognostic 
factor for overall survival while the pre-operative level was less informative [93]. Modified 
Glasgow prognostic score was an independent prognostic factor for overall and cancer-free 
survival in 102 consecutive gastric cancer patients treated with resection [97]. Modified GPS 
was independent predictor of cancer-specific survival in 120 surgically treated gastric cancer 
patients [98]. The role of modified GPS in stage IV gastric cancer was confirmed by Mimatsu et 
al., who evaluated cancer-specific survival in 42 patients at stage IV, treated by palliative gas-
trectomy and chemotherapy. The modified GPS was associated with cancer-specific survival 
[99]. Pre-operative modified GPS retained prognostic value in elderly patients [92]. Assessing 
1710 surgically treated patients with gastric cancer, modified GPS was associated with post-
operative mortality [94]. However, high-sensitivity modified GPS was found to be superior 
prognostic predictor for overall survival compared to modified GPS having especially high 
prognostic importance in stage I and IV [100].
By some study designs, the informativity of GPS has been estimated lower. In comparison 
with NLR-PLR score, modified Glasgow prognostic index was not an independent prognos-
tic factor for survival of stage I–I gastric cancer patients [31]. In 224 patients receiving che-
motherapy for advanced gastric cancer, NLR and diffuse type histology were independent 
prognostic factors for overall survival while GPS was not. However, the median survival still 
was significantly longer in patients having GPS 0 in contrast to those having GPS 1 or 2 [24].
GPS and its variations retain the prognostic value in advanced cases. In 402 patients with 
advanced gastric adenocarcinoma treated by palliative chemotherapy, GPS was an indepen-
dent predictor of overall survival [101]. GPS was an independent predictor of cancer-specific 
and progression-free survival in 83 patients having advanced gastric cancer and receiving 
chemotherapy. In low GPS group, favourable response to chemotherapy can be obtained 
[102]. In patients affected by stage IV gastric cancer and treated by chemotherapy, higher 
modified Glasgow prognostic score was associated with shorter overall survival (along with 
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lower level of albumin, elevated concentration of C-reactive protein, high absolute number of 
neutrophilic leukocytes and elevated NLR). In multivariate analysis, modified Glasgow prog-
nostic score was identified as an independent prognostic factor along with NLR, presence 
of lymph node metastasis and histological subtype [69]. In 68 patients affected by advanced 
gastric cancer and treated by chemotherapy with or without irradiation, high GPS predicted 
shorter survival [103]. High GPS was an independent prognostic factor in 384 inoperable 
advanced or metastatic gastric cancer patients treated with chemotherapy. The value of GPS 
was higher than that of NLR, PLR or CRP [68]. In 125 patients with recurrent or metastatic 
gastric cancer placed on single agent chemotherapy because of poor performance status, GPS 
had independent prognostic value [104]. In 91 metastatic or recurrent gastric cancer patients 
treated by palliative chemotherapy, GPS was significantly associated with survival. The dif-
ferences were also biologically remarkable: the median survival was 12.3 months if GPS was 
0 but only 2.9 if GPS was 2 [105].
Recently, a meta-analysis was carried out including 14 studies and 5579 gastric cancer patients. 
High GPS was significantly associated with poor overall survival (hazard ratio 1.51; 95% CI 1.37–
1.66), and disease-free survival (HR 1.45; 95% CI = 1.26–1.68) as reported by Zhang et al. [106].
Glasgow prognostic score has been further developed into different complex scores. Thus, com-
plex predictive score regarding survival was elaborated, based on NLR and modified Glasgow 
prognostic score in patients with metastatic gastric adenocarcinoma treated by chemotherapy, 
after independent prognostic value of both parameters was justified in a group of 256 patients 
[26]. The design of studies devoted to GPS in gastric carcinoma is summarised in Table 5.
5.2. Association with tumour features
5.2.1. Local tumour spread: T
In 88 patients undergoing only surgical treatment, increasing GPS was associated with higher 
T and resection line status [96]. In a recent meta-analysis, association between high GPS and 
high TNM stage was found. Although the association with lymph node metastases (OR 4.60; 
95% CI = 3.23–6.56) was significant, there was no association with T [106].
5.2.2. Metastases in regional lymph nodes: N
In a recent meta-analysis including 14 studies and 5579 gastric cancer patients, high GPS was 
significantly associated with presence of lymph node metastases (OR 4.60; 95% CI = 3.23–6.56) 
as well as with lymphatic (OR 3.04; 95% CI = 2.00–4.62) invasion [106].
5.2.3. Presence of distant metastases: M
In a homogeneous group of 88 gastric cancer patients undergoing only surgical treatment, 
increasing GPS was associated with presence of synchronous distant metastases and venous 
invasion [96].
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Group Score Target References
Characteristics Size
Meta-analysis 14 studies
5579 patients
GPS OS, CFS
TNM stage, N
Lymphatic invasion
Venous invasion
[106]
Meta-analysis 7 studies
3206 patients
mGPS OS
Lymphatic invasion
Venous invasion
[109]
Original studies of surgically treated GC
Stage I–II GC, treated by 
curative resection
305 mGPS OS [31]
GC undergoing surgical 
treatment only
88 GPS T, M, R; Venous 
invasion
Perioperative 
mortality
OS
[96]
GC patients subjected to 
surgical treatment
207 GPS OS [63]
Surgically treated GC 
patients with normal 
CEA level
425 GPS OS [91]
GC patients subjected to 
gastrectomy
236 HS-GPS Clinical and 
pathological 
parameters
OS
[93]
GC patients subjected to 
gastrectomy
552 GPS
HS-GPS
Clinical and 
pathological 
parameters
OS
[100]
Consecutive GC patients 
undergoing surgical 
treatment
102 mGPS OS
CFS
[97]
GC patients subjected to 
gastrectomy
294 mGPS OS [92]
Surgically treated GC 
patients
1017 GPS OS
Post-operative 
complications
[95]
Surgically treated GC 
patients
1710 mGPS OS [94]
Surgically treated GC 
patients
120 mGPS CSS [98]
Surgically treated GC 
patients, stage III
324 GPS CFS
OS
[43]
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Group Score Target References
Characteristics Size
Original studies of advanced GC
Chemotherapy for 
advanced GC
224 GPS OS [24]
Advanced GC treated 
with chemo- or 
chemoradiotherapy
68 GPS OS [103]
Metastatic GC treated by 
chemotherapy
256 mGPS OS [26]
GC patients at stage 
IV, treated by palliative 
gastrectomy
42 mGPS CSS [99]
Metastatic or 
recurrent GC patients 
considered for palliative 
chemotherapy
91 GPS OS [105]
Inoperable advanced or 
metastatic GC patients 
receiving first-line 
chemotherapy
384 GPS OS [68]
Advanced GC patients 
treated by single agent 
palliative chemotherapy 
due to poor performance
125 GPS OS [104]
Metastatic GC treated by 
palliative chemotherapy
104 mGPS OS [69]
Advanced GC treated by 
chemotherapy
83 GPS CSS, PFS [102]
Advanced recurrent or 
metastatic GC patients 
receiving first-line 
palliative chemotherapy
402 GPS PFS
OS
[101]
GC patients with vs. 
without cachexia vs. 
controls
90 (30 vs. 30 vs. 30) GPS Cachexia, adipokines [107]
Inoperable GC subjected 
to chemotherapy
71 GPS Predicting metastasis [108]
Abbreviations: GC, gastric cancer; mGPS, modified Glasgow prognostic score; OS, overall survival; GPS, Glasgow 
prognostic score; T, local tumour spread by tumour-nodes-metastasis (TNM) classification; M, presence of distant 
metastasis by TNM classification; R, resection line status; CEA, carcinoembryonic protein; HS-GPS, high sensitivity 
Glasgow prognostic score; CFS, cancer-free survival; CSS; cancer-free survival; PFS, progression-free survival; TNM, 
tumour-nodes-metastasis classification; vs, versus; N, regional lymph node status by TNM classification.
Table 5. The design of studies devoted to Glasgow prognostic score in gastric cancer.
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5.2.4. TNM stage
Assessing 1710 patients with gastric cancer, modified GPS was associated with advanced 
stage [94]. Elevated GPS has been reported in gastric cancer patients having cachexia; higher 
stage was also observed in cachectic patients [107]. However, GPS did not differ between 
metastatic and non-metastatic gastric cancer cases. Although the study group was small con-
sisting of only 43 metastatic and 28 non-metastatic cases, a novel score based on pre-albumin 
and CRP, showed significant differences [108]. In a recent meta-analysis including 14 studies 
and 5579 gastric cancer patients, elevated GPS was significantly associated with high TNM 
stage (odds ratio 3.09; 95% CI = 2.11–4.53) as reported by Zhang et al. [106].
5.2.5. Manifestations of invasive growth
In a homogeneous group of 88 gastric cancer patients undergoing only surgical treatment, 
increasing GPS was associated with presence of venous invasion [96]. In a recent meta-analysis 
including 14 studies and 5579 gastric cancer patients, high GPS was significantly associated 
with lymphatic (OR 3.04; 95% CI = 2.00–4.62) and venous (OR 3.56; 95% CI = 1.81–6.99) inva-
sion [106]. In a meta-analysis devoted to the modified Glasgow prognostic score, higher rates 
of lymphatic (OR 2.51; 95% CI = 1.80–3.51) and venous (OR 2.63; 95% CI = 1.35–5.11) invasion 
were found in patients in whom the score was at least 1 [109].
5.3. Meta-analyses of Glasgow prognostic score and its modifications in gastric cancer
Recently, a meta-analysis was carried including 14 studies and 5579 gastric cancer patients. 
High GPS was significantly associated with poor overall survival (hazard ratio 1.51; 95% CI 
1.37–1.66), and disease-free survival (HR 1.45; 95% CI = 1.26–1.68) as well as with high TNM 
stage (odds ratio 3.09; 95% CI = 2.11–4.53), N+ (OR 4.60; 95% CI = 3.23–6.56), lymphatic (OR 
3.04; 95% CI = 2.00–4.62) and venous (OR 3.56; 95% CI = 1.81–6.99) invasion [106].
In a meta-analysis devoted to the modified Glasgow prognostic score, worse overall survival 
(odds ratio OR 2.54; 95% CI = 1.62–3.98 for mGPS = 1 and OR 12.02; 95% CI 6.79–21.28 for 
mGPS = 2), higher rates of lymphatic (OR 2.51; 95% CI = 1.80–3.51) and venous (OR 2.63; 95% 
CI = 1.35–5.11) invasion were found in patients in whom the score was not zero [109].
6. Fibrinogen in gastric cancer evaluation
The association between malignant solid tumours and disturbances of blood clotting is well-
known. In addition, fibrinogen is an acute phase reactant glycoprotein [110]. Consequently, 
the presence of hyperfibrinogenaemia in gastric cancer patients can be almost expected. 
Indeed, increased levels of fibrinogen have been identified and explored regarding the prog-
nostic value or the association with tumour parameters. The studies range from historical to 
up-to-dated and cover aspects of patient’s survival, tumour progression, diagnostic value, 
estimates of tumour burden and insights into novel treatment options.
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Elevated concentration of fibrinogen in the serum of gastric carcinoma patients has negative 
prognostic value regarding several aspects of survival—overall and cancer-free survival. The 
independent prognostic value of increased fibrinogen level has been demonstrated in 351 
surgically treated gastric cancer patients. The hazard ratio was 2.61 (95% CI = 1.18–5.76) as 
reported by Suzuki et al. [111]. The independent prognostic role was confirmed in another 
large surgically treated cohort of 1196 gastric cancer patients [112]. Applying ROC-identified 
cut-off (3.9 g/L), high fibrinogen level was significantly associated with overall survival in 
multivariate analysis [113]. In patients who underwent curative gastrectomy, hyperfibrino-
genaemia (reaching or exceeding 350 mg/dL) was associated not only with overall but also 
cancer-free survival. By multivariate analysis, fibrinogen level again was an independent 
prognostic factor along with pTN [33].
Classic studies have explored the diagnostic meaning of hyperfibrinogenaemia resulting in con-
clusion that fibrinogen level is significantly elevated in gastric cancer patients but not in individ-
uals having gastric or duodenal peptic ulcer. Such reports stem back as far as to 1975 [114]. Later, 
it was repeatedly confirmed that fibrinogen levels in gastric cancer are higher than in controls, 
even if the tumour was non-metastatic. The mean levels in cancer patients vs. control individuals 
were 505 vs. 336 mg/dL [115]. Nowadays, the ongoing research has identified fibrinogen frag-
ments that could potentially serve as serum markers of gastric cancer. Fibrinogen fragments, e.g., 
carboxyl terminal fraction of fibrinogen alpha, have been tested as a serum marker of gastric can-
cer in comparison with healthy controls and individuals affected by chronic gastritis [116, 117].
A 15-amino acid peptide of the fibrinogen alpha chain, fibrinostatin, has anti-angiogenic 
properties; thus therapeutic applications have been hypothesised [118].
Regarding the local events within the tumour, fibrinogen has been identified in tumour stroma 
as early as 1984 [119, 120] while fibrin and D-dimers are found in the invasive front [120].
Fibrinogen level parallels the tumour burden, correlates with advanced TNM stage [112] and 
is associated with adjacent organ involvement [121]. In a recent considerable cohort of 1090 
gastric cancer patients treated by gastrectomy, high fibrinogen level (exceeding the ROC-
identified cut-off at 3.9 g/L) was significantly associated with tumour size, T, N and TNM 
stage [113]. Fibrinogen shows statistically significant associations with the invasion depth 
of gastric cancer confirmed by several other studies focusing on T [122–124]. Several studies 
have identified meaningful association with presence of metastasis in lymph nodes [122–124]. 
The association with tumour spread has also been confirmed, regarding the presence of dis-
tant metastases [122].
The logical next step is incorporation of fibrinogen measurements into combined scores that 
could be used to assess the prognosis or tumour spread. A complex score comprising evalu-
ation of hyperfibrinogenemia (exceeding 400 mg/dL) and elevated NLR (exceeding 3.0) was 
associated with shorter survival. The combined score showed significantly different results in 
patients developing progressive disease despite chemotherapy or chemoradiotherapy [103]. 
Similar score comprising evaluation of hyperfibrinogenemia (reaching or exceeding 305 mg/dL) 
and elevated NLR (reaching or exceeding 2.34) was significantly associated with invasion depth, 
lymph node metastasis, lymphovascular invasion and stage [110]. Coagulation score based on 
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the assessment of fibrinogen and D-dimer levels, was significantly associated with overall and 
cancer-free survival as well as with recurrence and development of liver metastases [125].
Other blood clotting parameters show similar associations with patient’s prognosis and tumour 
burden. Thus, D-dimers [126, 127] and thrombocytosis [128] have prognostic role in gastric can-
cer. In turn, D-dimers and prothrombin time are associated with lymph node involvement [129].
7. Application of SIR in complex scoring systems for gastric cancer
SIR parameters have been incorporated in diverse complex scores that allow reaching higher 
diagnostic value (see also Tables 6–7).
A complex score, based on fibrinogen (cut-off 400 mg/dL) and NLR (cut-off 3.0) levels, was 
applied to predict the effect of chemotherapy or chemoradiotherapy in advanced gastric can-
cer. The created score indeed was significantly higher in patients having cancer progression 
during treatment; it also was an independent prognostic factor by multivariate analysis [103]. 
The same authors have elaborated similar combined score, based on the same parameters 
which by different cut-off levels are adjusted for another research target. The fibrinogen-NLR 
score at cut-off 305 mg/dL and 2.34, respectively, was significantly associated with depth of 
tumour invasion, lymph node metastasis, lymphatic and venous invasion and tumour stage. 
The 5-year survival rates by score categories 0 vs. 1 vs. 2 were 92.9, 84.1 and 66.5%; the differ-
ences being statistically significant [110].
The coagulation score, recently proposed by Kanda et al., distinguished high-risk patients having 
low overall and cancer-free survival. High coagulation score was also an independent prognostic 
factor for recurrence and was associated with liver metastasis as the initial recurrence [125]. It is in 
accordance with the observation that D-dimer is associated with metastatic tumour spread both 
in murine gastric carcinoma models and in patients having visceral metastasis [130].
The score developed by Ishizuka et al. was based on platelet count and NLR to predict post-
operative survival. The score classified patients into 3 groups: 0 vs. 1 vs. 2 had post-operative 
survival of 1676 vs. 1310 vs. 1050 days. The differences were statistically significant. The 
cancer-specific survival also was significantly different by the score levels. The sensitivity 
and accuracy of the presented score in regard to survival was higher than the informativity of 
clinical and pathological parameters—carcinoembryonic antigen CEA, CA19-9, venous and 
lymphatic invasion and lymph node metastasis [29].
NLR-PLR score can be used to assess overall survival in gastric cancer patients diagnosed at 
stage I–II. This score was an independent prognostic factor while mGPS, the prognostic nutri-
tional index and combination of platelet count and NLR were not. The score had the highest 
area under ROC curve in comparison with the listed other scores. The hazard ratio associated 
with NLR-PLR score was 1.51 (95% CI = 1.02–2.24). Interestingly, there was a trend to shorter 
mean OS in stage I patients having NLR-PLR score of 2 than in stage II patients scored 0: 89 
months vs. 127 months. The score retained prognostic value in stage I and II [31].
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The score based on albumin and NLR was elaborated to improve the evaluation of overall sur-
vival. The resulting score was independently associated with overall survival. It had higher 
diagnostic value than NLR, PLR and GPS, as shown by higher area under ROC curve. The 
overall survival by score values 0 vs. 1 vs. 2 was 44.9% vs. 29.8% vs. 20.3%, respectively [30].
Target Score description References
Lymph node metastases in early 
gastric cancer
PLR (cut-off 106, based on ROC 
analysis), age, grade, depth of invasion 
and tumour size
[72]
Survival of early gastric cancer 
patients
NLR (cut-off 2.1), PLR (cut-off 120) [31]
Lymph node metastases Independent predictive factors (for 
lymph node metastasis) that can be 
determined preoperatively: NLR 
(cut-off 1.59), PLR (cut-off 155.67), T/
depth of invasion, macroscopic type 
(Bormann), tumour size
[55]
Overall survival Albumin (cut-off 35 g/L), NLR  
(cut-off 2.3)
[30]
Cancer-specific survival (CSS) and 
cancer-free survival (CFS)
Nomogram including independent 
predicting factors:
(1) for CSS: NLR, age, tumour stage, 
presence of lymph node metastases, 
presence of distant metastases;
(2) for CFS: NLR, tumour stage, 
presence of distant metastases, family 
history of gastric cancer; CA 19-9 level.
[47]
Overall survival and chemotherapy 
response
NLR (cut-off 3.0) and fibrinogen  
(cut-off 400 mg/dL)
[103]
Prognosis and cancer characteristics NLR (cut-off 2.34) and fibrinogen  
(cut-off 305 mg/dL)
[110]
Overall survival Canton score: 1prognostic nutritional 
index (PNI; cut-off 48), platelet count 
(cut-off 3 × 1011/L) and NLR (cut-off 
1.83)
[45]
Overall and cancer-specific survival Platelet count and NLR [29]
Overall and cancer-free survival
Recurrence
Metachronous liver metastases
Coagulation score: increased level of 
fibrinogen and D-dimers
[125]
Overall survival NLR, mGPS and patient-generated 
subjective global assessment score
[26]
Abbreviations: PLR, platelet to lymphocyte ratio; ROC, receiver operating characteristic curve; NLR, neutrophil to 
lymphocyte ratio; T, local spread of primary gastric cancer by tumour-nodes-metastasis (TNM) classification; CSS, 
cancer-specific survival; CFS, cancer-free survival; mGPS, modified Glasgow prognostic score.
1PNI = albumin (g/L) + 5 × total lymphocyte count (×109/L).
Table 6. Application of SIR in complex scoring systems for gastric cancer.
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Modified Glasgow prognostic score [31]
0 CRP ≤  10 mg/L irrespectively of albumin level
1 Albumin ≥ 35 g/L AND CRP > 10 mg/L
2 Albumin < 35 g/L AND CRP > 10 mg/L
Albumin—NLR score [30]
0 Albumin ≥ 35 g/L AND NLR < 2.3
1 Albumin ≥ 35 g/L AND NLR ≥ 2.3 OR
Albumin < 35 g/L AND NLR < 2.3
2 Albumin < 35 g/L AND NLR ≥ 2.3
NLR—PLR score [31]
0 Both values are low: NLR < 2.1 AND PLR < 120
1 Only one elevated value: NLR ≥ 2.1 AND PLR < 120 OR 
NLR < 2.1 AND PLR ≥ 120
2 Both values are elevated: NLR ≥ 2.1 AND PLR ≥ 120
Inflammation and nutrition based score [26]
0–2 Favourable group
3–4 Intermediate risk
5–6 High risk
Definitions of the score components:
NLR > 3 equals 1, otherwise scored 0
mGPS > 1 equals 3, otherwise scored 0
Patient-Generated Subjective Global Assessment C equals 
2, otherwise (A or B) scored 0
Hyperfibrinogenemia—NLR score [103]
0 NLR ≤ 3.0 AND fibrinogen ≤ 400 mg/dL
1 NLR >3.0 OR fibrinogen > 400 mg/dL
2 NLR >3.0 AND fibrinogen > 400 mg/dL
Hyperfibrinogenemia—NLR score II [110]
0 NLR < 2.34 AND fibrinogen > 305 mg/dL
1 NLR ≥ 2.34 OR fibrinogen ≥ 305 mg/dL
2 NLR ≥ 2.34 AND fibrinogen ≥ 305 mg/dL
Combined score to predict lymph node metastases [55]
0–155 Low risk
>156 High risk
Definitions of the score components:
Tumour size ≥ 3 cm scored 39, otherwise scored 0
Macroscopic type: early vs. Borrmann I–II vs. Borrmann 
III–IV scored 0 vs. 32 vs. 59
PLR > 155.67 scored 28, otherwise scored 0
NLR > 1.59 scored 28, otherwise scored 0
Depth of invasion: T3—4 scored 60, otherwise scored 0
Combined score to predict lymph node metastases [72]
0–11 Low risk
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The inflammation and nutrition-based score was elaborated to predict overall survival in 
patients diagnosed with metastatic gastric cancer. According to this score, patients were clas-
sified into favourable, intermediate and high-risk groups exhibiting the median overall sur-
vival of 27.6 vs. 13.2 vs. 8.2 months. The respective two-year survival rates were 52% vs. 16% 
vs. 3%. The ROC curve analysis confirmed that the novel score has higher informativity than 
any of its components [26].
Deng et al. elaborated complex nomograms to predict cancer-specific and cancer-free survival 
in surgically treated gastric cancer patients [47].
12–20 High risk
Definitions of the score components:
Age ≥ 65 scored 3, otherwise scored 0
Tumour size ≥ 1.8 cm scored 4, otherwise scored 0
Grade: G3 scored 5, otherwise scored 0
Depth of invasion: submucosa scored 3, while mucosa 
scored 0
PLR > 106 scored 3, otherwise scored 0
Canton score [45]
0 No high-risk parameters: 1PNI ≥ 48 AND NLR ≤ 1.83 
AND PLT ≤ 3 × 1011/L
1 One high-risk parameter:
PNI < 48 AND NLR ≤ 1.83 AND PLT ≤ 3 × 1011/L
PNI ≥ 48 AND NLR > 1.83 AND PLT ≤ 3 × 1011/L
PNI ≥ 48 AND NLR ≤ 1.83 AND PLT > 3 × 1011/L
2 Two high-risk parameters:
PNI < 48 AND NLR > 1.83 AND PLT ≤ 3 × 1011/L
PNI < 48 AND NLR ≤ 1.83 AND PLT > 3 × 1011/L
PNI ≥ 48 AND NLR > 1.83 AND PLT > 3 × 1011/L
3 Three high-risk parameters: PNI < 48 AND NLR > 1.83 
AND PLT > 3 × 1011/L
Platelet count and NLR score [29]
0 No elevated parameters: PLT ≤ 300 × 103/mkL AND NLR 
≤ 3
1 One elevated parameter: PLT > 300 × 103/mkL OR NLR >3
2 Two elevated parameters: PLT > 300 × 103/mkL AND 
NLR >3
Coagulation score [125]
0 Normal level of D-dimer AND fibrinogen
1 Increased level of either D-dimer OR fibrinogen
2 Increased level of both D-dimer AND fibrinogen
Abbreviations: CRP, C-reactive protein; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; mGPS, 
modified Glasgow prognostic score; T, local spread of primary gastric cancer by tumour-nodes-metastasis (TNM 
classification), G, grade; PNI, prognostic nutritional index; PLT, platelet count.
1PNI = albumin (g/L) + 5 × total lymphocyte count (×109/L).
Table 7. The definitions of complex scores.
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Pang et al. developed complex system to predict lymph node metastases based on those 
tumour and systemic parameters that were independently associated with N+ and could be 
detected preoperatively. The point system was based on hazard ratios detected by logistic 
regression analysis. Youden Index was applied to detect the cut-off of the novel combined sys-
tem. Finally, the developed score had specifity of 72.4%, sensitivity 82.7%, positive predictive 
value 88.7% and negative predictive value 61.5%. Besides the informative value of the score 
itself, the mathematical model of score design is flawless [55].
Lou et al. developed score to predict lymph node metastases in early gastric cancer. The scor-
ing system reached reasonable accuracy of 0.817 when evaluating prospective cases [72].
The Canton score was created to predict overall survival after gastrectomy. The novel score 
possessed higher AUC than the classic parameters. The HR for Canton score values 1 vs. 2 vs. 
3 (in comparison to 0) were 1.08 (95% CI = 0.80–1.45) vs. 1.55 (95% CI = 1.15–2.10) vs. 1.64 (95% 
CI = 1.14–2.36) as reported by Sun et al. [45].
8. Conclusions
Gastric cancer induces systemic inflammatory reaction. The biological background is com-
plex, involving bone marrow activation, development of immune-suppressing immature 
myeloid cells, generation of pre-metastatic niches and neutrophil extracellular trap formation 
from externalised DNA network in bidirectional association with platelet activation. These 
mechanisms have been demonstrated in general studies of carcinogenesis as well as in animal 
models and human studies of gastric cancer.
Systemic inflammatory reaction can be easily evaluated by simple, patient friendly and eco-
nomically non-demanding blood tests practically lacking complications. These tests could 
be broadly classified as cellular and protein-based. Among cellular tests, neutrophil to lym-
phocyte ratio is the most widely explored followed by platelet to lymphocyte ratio. Glasgow 
prognostic score is the prototype of protein-based test.
Although controversies still exist, most researchers have recognised the independent prog-
nostic value of NLR, encompassing overall, cancer-specific, cancer-free or progression-free 
survival both in early and advanced gastric cancer. NLR can bring significant prognostic 
information in surgically treated individuals, in case of combined treatment and in patients 
receiving only chemotherapy.
NLR shows associations with TNM parameters. Thus, it can be incorporated in patient’s 
evaluation for tumour burden. The possibility to predict serosal invasion, peritoneal and/or 
metastatic spread can be an adjunct to avoid inappropriate attempts of technically impossible 
gastrectomy. Lymph node status can be predicted as well.
PLR and GPS also possess diagnostic and prognostic information in gastric cancer patients, as 
well as show correlations with tumour parameters.
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The cut-offs for NLR and PLR show significant variability. Mostly, the cut-off levels are iden-
tified either based on ROC analysis and Youden Index, or the median is selected for cut-off. 
Less frequently, the 75th percentile is applied.
Combined scores appear, based on SIR data in complex with patient’s characteristics as well 
as tumour features. The informativity of such scores is generally higher than that of separate 
components; therefore, wider testing of these scores in different populations should be neces-
sary to bring the promising novel scores to clinical application.
Abbreviations
AUC Area under curve
CD Cluster of differentiation
CEA Carcinoembryonic antigen
CI Confidence interval
CRP C-reactive protein
DNA Deoxyribonucleic acid
ECOG Eastern Cooperative Oncology Group
G Grade
GPS Glasgow prognostic score
HR Hazard ratio
IL Interleukin
LMR Lymphocyte to monocyte ratio
LWR Lymphocyte to white cell ratio
M Presence or absence of distant metastases in accordance with TNM classification
mGPS Modified Glasgow prognostic score
MWR Monocyte to white cell ratio
N  Status of regional lymph nodes regarding metastases in accordance with TNM 
classification
NLR Neutrophil to lymphocyte ratio
OR Odds ratio
PLR Platelet to lymphocyte ratio
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R Resection line status regarding presence or absence of tumour
ROC Receiver operating characteristics
SIR Systemic inflammatory reaction
T Local tumour spread in accordance with TNM classification
TNF Tumour necrosis factor
TNM Tumour-node-metastasis classification to reflect the extent of tumour growth and spread
USA The United States of America
vs. versus
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